Surgical Menopause Clinical Trial
Official title:
The Effect of Hormone Therapy on Serum Ischemia Modified Albumin Levels in Surgical Menopausal Women
Women suffer from cardiovascular diseases 10 years later than men, therefore female sex has
been considered as a 'protective factor'. However, the risk of cardiovascular disease in
women increases rapidly after menopause and the declining levels of endogenous estrogen is
thought to be the causative factor. Furthermore, Postmenopausal hormone therapy (HT)
decreases the severity and intensity of menopausal symptoms and improves women's quality of
life. Until the last 10 years, based on the results of observational studies, postmenopausal
HT may protect women against cardiovascular events and decrease the risk of coronary artery
disease by 35-50%. However, recent randomized primary and secondary prevention trials did not
support the cardioprotective effect of HT.
The aim of this study is to assess the effect of hormone therapy on serum ischemia modified
albumin (IMA) levels. Thirty surgical menopausal women who admitted to Karadeniz Technical
University, Faculty of Medicine, Department of Obstetrics and Gynecology during 1-year period
and diagnosed as menopause and planned to have hormone therapy for menopausal symptoms were
enrolled for this prospective study. The serum İMA levels were recorded before and after (3
months, 6 months, 12 months later) hormone treatment (2 mg Estradiol Hemihidrat).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05809960 -
The Effect of Nursing Support Program for Women in Surgical Menopause on Their Life Quality
|
N/A | |
| Completed |
NCT05920655 -
Comparison of Ocular Changes by Surgical Menopause Using Optical Coherence Tomography (OCT)
|
||
| Enrolling by invitation |
NCT03835793 -
Health After eaRly Menopause Due to Oophorectomy
|